FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer’s disease

Abstract

Purpose We report the first clinicopathological series of longitudinal FDG-PET scans in post-mortem (PM) verified cognitively normal elderly (NL) followed to the onset of Alzheimer's-type dementia (DAT), and in patients with mild DAT with progressive cognitive deterioration. Methods Four NL subjects and three patients with mild DAT received longitudinal clinical, neuropsychological and dynamic FDG-PET examinations with arterial input functions.NL subjects were followed for 13±5 years, received FDG-PET examinations over 7±2 years, and autopsy 6±3 years after the last FDG-PET. Two NL declined to mild cognitive impairment (MCI), and two developed probable DAT before death. DAT patients were followed for 9±3 years, received FDG-PET examinations over 3±2 years, and autopsy 7±1 years after the last FDG-PET. Two DAT patients progressed to moderate-to-severe dementia and one developed vascular dementia. Results The two NL subjects who declined to DAT received a PM diagnosis of definite AD. Their FDG-PET scans indicated a progression of deficits in the cerebral metabolic rate for glucose (CMRglc) from the hippocampus to the parietotemporal and posterior cingulate cortices. One DAT patient showed AD with diffuse Lewy body disease (LBD) at PM, and her last in vivo PET was indicative of possible LBD for the presence of occipital as well as parietotemporal hypometabolism. Conclusion Progressive CMRglc reductions on FDG-PET occur years in advance of clinical DAT symptoms in patients with pathologically verified disease. The FDG-PET profiles in life were consistent with the PM diagnosis.

Inhibition of glycolysis attenuates 4-hydroxynonenal-dependent autophagy and exacerbates apoptosis in differentiated SH-SY5Y neuroblastoma cells

“…Cellular bioenergetics at the level of the mitochondrion is intimately linked to glucose metabolism through the provision of pyruvate as a substrate for respiration and NADPH for protection against oxidative stress. Importantly, glucose metabolism is altered in stroke and neurodegenerative diseases, [33][34][35][36][37] emphasizing the need for understanding the potential link between cellular bioenergetics, autophagy and neuronal viability. In support of this concept, our published studies in differentiated SH-SY5Y neuroblastoma cells have shown that HNE decreases mitochondrial function and glycolysis, and can cause cell death.…”

Targeting the Prodromal Stage of Alzheimer's Disease: Bioenergetic and Mitochondrial Opportunities

“…In vitro and in vivo preclinical AD models indicate that deficits in mitochondrial function, metabolic enzyme expression and activity, cerebral glucose metabolism, and free radical scavenging are coupled with mitochondrial Aβ load and Aβ-binding alcohol dehydrogenase (ABAD) expression [12,13,24,25]. Importantly, clinical studies indicate that mitochondrial deficits observed in preclinical models are evident in human-derived platelets [14,15,[26][27][28][29]. The antecedent decline in mitochondrial function and brain metabolism indicates an early and potentially causal role in AD pathogenesis.…”

Glucose deprivation increases tau phosphorylation via P38 mitogen‐activated protein kinase

“…The CNS is particularly vulnerable to hypoglycemic damage, and changes in glucose metabolism have been observed in a variety of neurodegenerative conditions associated with dementia (Peppard et al ., 1990, 1992; De Leon et al ., 2007; Mosconi et al ., 2007). In particular, positron emission tomography imaging studies have shown that glucose utilization is dramatically lower in AD, compared to aged‐matched, nondemented brain (Mosconi et al ., 2009; Landau et al ., 2012). Moreover, postmortem analysis of AD brain shows down‐regulated expression of mitochondrial enzymes indicating a deficiency in energy metabolism (Soane et al ., 2007).…”